CancerNetwork and the journal ONCOLOGY present an exclusive interview with Dr. Kimberly Blackwell, Duke Cancer Institute, who discusses some of the most important information to come out of this year’s meeting and talks about the future of breast cancer research.

CancerNetwork speaks with Hagop Kantarjian, MD, M.D. Anderson Cancer Center, who shares his impressions of some of the highlights of this year’s ASCO meeting with regard to hematologic malignancies.

CancerNetwork presents an exclusive interview with Joel W. Neal, MD, PhD, who discusses some of the most important information to come out of this year’s meeting and talks about the future of lung cancer research.

Impressive interim results from a phase Ib/II trial of ibrutinib, a selective Bruton tyrosine kinase inhibitor, in patients with chronic lymphocytic leukemia (CLL) were reported at ASCO.

Bendamustine plus rituximab should be considered as the preferred first-line treatment of follicular and indolent lymphomas, and the elderly with mantle cell lymphoma.

Updated clinical data from the pivotal phase II global PACE trial of ponatinib confirm its impressive antileukemic activity in patients with chronic myeloid leukemia or Philadelphia-chromosome-positive acute lymphoblastic leukemia at all stages who are resistant or intolerant to dasatinib or nilotinib.

Women previously treated for HER2-positive breast cancer have lower rates of relapse when given a novel peptide vaccine. The AE37 vaccine showed a 43% risk reduction in these patients after 22 months of follow-up in a phase IIb clinical trial.

The results of a randomized phase III trial show paclitaxel beat two newer chemotherapies, nab-paclitaxel and ixabepilone in the treatment of metastatic breast cancer patients who have not had prior systemic therapies.

The idea of adding the targeted EGFR inhibitor cetuximab to standard chemotherapy took a hit, as results from the SELECT phase III trial showed no improvement in efficacy when cetuximab was combined with pemetrexed in patients with recurrent or progressive non–small-cell lung cancer.

Final results of the PARAMOUNT study in non-squamous non–small-cell lung cancer confirmed improved survival with continuation pemetrexed maintenance therapy.

In patients with advanced NSCLC and without any mutation in the EGFR gene, docetaxel provides significantly improved progression-free survival compared to erlotinib, according to a phase III randomized trial.

In this exclusive interview, Michael B. Atkins, MD, director of the Georgetown Lombardi Comprehensive Cancer Center, discusses some of the most important melanoma research to come out of this year’s ASCO meeting and talks about the future of melanoma therapies.

At the ASCO annual meeting, researchers presented persuasive evidence that a new class of targeted agents—MEK inhibitors—may warrant inclusion in the growing armamentarium for patients with advanced BRAF-mutated melanoma.

Women with metastatic HER2-positive breast cancer treated with a taxane-based chemotherapy in combination with trastuzumab as a first-line of treatment have a longer progression-free survival compared to chemotherapy in combination with lapatinib (Tykerb)

Data from the phase III BREAK-3 and the phase II BREAK-MB trials of dabrafenib establish the drug as the second BRAF inhibitor for BRAF V600E-mutated melanoma.